Evaluación de la prescripción y uso de medicamentos supresores de ácido en hospitales centrales en la región de Abha, Arabia Saudita

Autores/as

  • Khaled Mohammed Alakhali Dr. Khaled Mohammed Al-Akhali, PhD Assistant Professor Department of Clinical Pharmacy Faculty of pharmaceutical science Malaysia, Kuala Lumpur UCSI University
  • Hadeel M. Bayoumi Department of Clinical Pharmacy, College of Pharmacy, King Khalid University
  • Elham S. Abunakhaa Department of Clinical Pharmacy, College of Pharmacy, King Khalid University
  • Manal Ahmed Department of Clinical Pharmacy, College of Pharmacy, King Khalid University
  • Nada S. Alqahtani Department of Clinical Pharmacy, College of Pharmacy, King Khalid University
  • Rasha A. Jaber Department of Clinical Pharmacy, College of Pharmacy, King Khalid University
  • Sahar S. Alasmari Department of Clinical Pharmacy, College of Pharmacy, King Khalid University
  • Subhya A. Alshahrani Department of Clinical Pharmacy, College of Pharmacy, King Khalid University
  • Zohoor A. Alshahrani Department of Clinical Pharmacy, College of Pharmacy, King Khalid University

DOI:

https://doi.org/10.30827/ars.v60i2.8687

Palabras clave:

Acid, suppressive, drugs, prescription

Resumen

Objetivo: El objetivo de este estudio fue estudiar y evaluar las indicaciones de los medicamentos supresores de ácidos y averiguar el porcentaje de recetas irracionales con medicamentos supresores de ácidos.

Material / Métodos: es un estudio observacional prospectivo realizado en los Hospitales de las Fuerzas Armadas del Sur y en el Hospital de Maternidad Abha, ambos en Abha en la región de Assir (Arabia Saudita). El tamaño muestral del estudio fue de 185 pacientes. Se revisaron las hojas de casos de orden de prescripción de los pacientes para la prescripción de medicamentos supresores de ácido y se tomaron los datos pertinentes. Se identificó la edad de los pacientes mayores de 18 años. La duración del estudio fue de 8 semanas, entre mayo y junio de 2017.

Resultados: nuestros resultados mostraron que la mayoría de las prescripciones de inhibidores de la bomba de protones (68,1%) eran injustificables y que este era el fármaco supresor de ácido más comúnmente prescrito para los pacientes (97,8%). La frecuencia de prescripción para los trastornos del espectro autistas en nuestro estudio, fue mayor en pacientes con un factor de riesgo existente y fue recomendada principalmente por los médicos como medicamentos concomitantes (67,6%). Los medicamentos concomitantes más comunes que se usaron con los inhibidores de la bomba de protones fueron los antiinflamatorios no esteroideos (29.2%) en los cuales la aspirina supuso el 13,5% de los antiinflamatorios no esteroideos prescritos, seguidos por los antimicrobianos (9.2%)

Conclusión: los medicamentos supresores de ácido son los medicamentos más comúnmente recetados sin indicaciones adecuadas, por lo que son irracionales. Basado en los resultados de este estudio, crear conciencia sobre el uso razonable de los medicamentos supresores del ácido es una necesidad.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Khaled Mohammed Alakhali, Dr. Khaled Mohammed Al-Akhali, PhD Assistant Professor Department of Clinical Pharmacy Faculty of pharmaceutical science Malaysia, Kuala Lumpur UCSI University

assistant professor in Clinical Pharmacy Department

Citas

Eriksson S, Långström G, Rikner L, Carlsson R and Naesdal J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis. Eur. J. Gastroenterol. Hepatol , 1995, 7 467-475.

Blume H, Donath F, Warnke A and Schug B. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf, 2006, 29(9) 769-84. Doi:10.2165/00002018-200629090-00002

Bashford JN, Norwood J and Chapman SR. Why patients are prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ, 1998, 15 317 (7156) 452-6

Julapalli VR and Graham DY. Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Dig Dis Sci, 2005, 50 1185-93. Doi: 10.1177/1756283X09352095

Katelaris PH. Proton pump inhibitors. Med. J. Aust. 1998, 169 (4) 208-11.

Reilly JP. Safety profile of the proton-pump inhibitors. Am. J. Health-Syst. Pharm., 1999, 56 (23 Suppl 4) 11-7. Doi:10.1093/ajhp/56.suppl_4.S11

Lewis SJ, Franco S, Young G, O and Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmcol Ther , 1996, 10 (4) 557-61.

Waldum HL, Brenna E, Kleveland PM, Sandvik AK and Syversen U. Review article: the use of gastric acid-inhibitory drugs, physiological and pathophysiological considerations. Aliment Pharmacol Ther 1993, 7 (6) 589-96.

Yang YX, Lewis JD, Epstein S and Metz DC. Long term proton pump inhibitor therapy and risk of hip fracture. JAMA, 2006, 296(24) 2947–53. Doi:10.1001/jama.296.24.2947

Eurich DT, Sadowski CA, Simpson SH, Marrie TJ and Majumdar SR. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med, 2010, 123 (1) 47-53. Doi:10.1016/j.amjmed.2009.05.032

Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997, 17 (1) 22-37.

Bashford JN, Norwood J and Chapman SR. Why patients are prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ, 1998, 317 (7156) 452-6.

Heidelbaugh JJ and Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in Non-ICU hospitalized patients. Am J Gastroenterol, 2006, 101:2200-5. Doi:10.1111/j.1572-0241.2006.00839.x

Sebastian SS, Kernan N, Qasim A, O’Morain CA and Buckley M. Appropriateness of gastric antisecretory therapy in hospital practice. Indian J Med Sci. 2004, 172:115-7

Ahmed Yacoob. Improper Use of Antisecretory drugs in a Tertiary Care Teaching Hospital: An Observational Study. Saudi J Gastroenterol , 2007, 13(3):124-128. Doi: 10.4103/1319-3767.33463

Brandhagen DJ, Phaley AM, Onstad GR, Freeman ML and Lurie N. Omeprazole use at an urban county teaching hospital. J. Gen Intern Med, 1995, 109:513-5.

Maclaren R, Obritsch MD, Sherman DS, Jung R and Fish DN. Assessing adherence to an intravenous pantoprazole guideline. J Pharm Technol, 2006, 22:15-21.

Nousheen, Tadvi NA and Shareef SM. Use of proton pump inhibitors in general practice: Is it rationale? IJMRHS, 2014, 3(1) 37-42

Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L and Bianchi Porro G. Hospital use of acid-suppressive medications and its fall out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther, 2003, 17 (12) 1503-6.

Ramirez E, Lei S, Borobia A, Pinana E, Fudio S, Munoz R and et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital, Curr Clin Pharmacol , 2010, 5(4):288-97.

Tasneem Sandozi. A Comparative Study of Cost Analysis of H2 Antagonists and Proton Pump Inhibitors in a Tertiary Care Hospital. RJPBCS, 2013, 4(5): 888-897

Baron TH, Ramirez B and Richter JE. Gastrointestinal motility disorders during pregnancy. Ann Intern Med, 1993, ;118(5):366-75

Hoogerwerf WA, Pasricha PJ. Pharmacotherapy of Gastric acidity, peptic ulcers, and gastroesophageal Reflux disease. In: Laurence L. Brunton, John S Lazo Keith L.Parker, eds. The Pharmacological basis of therapeutics; Goodman & Gilman, 2006, 11ed. 971-72.

Ahrens D, Chenot J-F, Behrens G, Grimmsmann T and Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol, 2010; 66(12):1265-71. Doi:10.1007/s00228-010-0871-9

Walker NM and McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci, 2001; 23(3):116-7.

Eid SM, Boueiz A, Paranji S, Mativo C, Landis RBA and Abougergi MS. Patterns and Predictors of Proton Pump Inhibitor Overuse among Academic and Non-Academic Hospitalists. Intern Med, 2010; 49 (23):2561-8.

Scagliarini R, Magnani E, Praticò A, Bocchini R, Sambo P and Pazzi P. Inadequate Use of Acid-Suppressive Therapy in Hospitalized Patients and Its Implications for General Practice. Dig Dis Sci, 2005; 50(12):2307-11. Doi:10.1007/s10620-005-3052-4

Molloy D, Molloy A, O’Loughlin C, Falconer M and Hennessy M. Inappropriate use of proton pump inhibitors. Ir J Med Sci, 2010; 179(1):73-5. Doi:10.1007/s11845-009-0426-1

Mat Saad AZ, Collins N, Lobo MM, O’Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59:31-4. Doi:10.1111/j.1742-1241.2004.00298.x

Law JK, Andrews CN and Enns R. Intravenous proton pump inhibition utilization and prescribing patterns escalation: a comparison between early and current trends in use. Gastrointest Endosc, 2009 ; 69:3-9.

Batuwitage BT, Kingham JGC, Morgan NE and Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83(975):66-8. Doi:10.1136/pgmj.2006.051151

Kumar A, Dalai CK, Ghosh AK and Ray M. Drug utilization study of co-administration of nonsteroidal anti-inflammatory drugs and gastroprotective agents in an orthopaedics outpatients department of a tertiary care hospital in West Bengal. IJBCP, 2013; 2(2):199-202.

Raghavendra B, Narendranath S, Ullal SD, Kamath R, Pai MR, Kamath S and et al. Trends in prescribing gastroprotective agents with non steroidal anti-inflammatory drugs in an Orthopaedic outpatient unit of a tertiary care hospital. J Clin Diagn Res, 2009; 3(3):1553-6.

Descargas

Publicado

2019-06-20

Cómo citar

1.
Alakhali KM, Bayoumi HM, Abunakhaa ES, Ahmed M, Alqahtani NS, Jaber RA, Alasmari SS, Alshahrani SA, Alshahrani ZA. Evaluación de la prescripción y uso de medicamentos supresores de ácido en hospitales centrales en la región de Abha, Arabia Saudita. Ars Pharm [Internet]. 20 de junio de 2019 [citado 29 de marzo de 2024];60(2):125-31. Disponible en: https://revistaseug.ugr.es/index.php/ars/article/view/8687

Número

Sección

Artículos Originales